Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Cadherin-11 blockade reduces inflammation-driven fibrotic remodeling and improves outcomes after myocardial infarction
Alison K. Schroer, … , Hind Lal, W. David Merryman
Alison K. Schroer, … , Hind Lal, W. David Merryman
Published September 19, 2019
Citation Information: JCI Insight. 2019;4(18):e131545. https://doi.org/10.1172/jci.insight.131545.
View: Text | PDF
Research Article Cardiology

Cadherin-11 blockade reduces inflammation-driven fibrotic remodeling and improves outcomes after myocardial infarction

  • Text
  • PDF
Abstract

Over one million Americans experience myocardial infarction (MI) annually, and the resulting scar and subsequent cardiac fibrosis gives rise to heart failure. A specialized cell-cell adhesion protein, cadherin-11 (CDH11), contributes to inflammation and fibrosis in rheumatoid arthritis, pulmonary fibrosis, and aortic valve calcification but has not been studied in myocardium after MI. MI was induced by ligation of the left anterior descending artery in mice with either heterozygous or homozygous knockout of CDH11, wild-type mice receiving bone marrow transplants from Cdh11-deficient animals, and wild-type mice treated with a functional blocking antibody against CDH11 (SYN0012). Flow cytometry revealed significant CDH11 expression in noncardiomyocyte cells after MI. Animals given SYN0012 had improved cardiac function, as measured by echocardiogram, reduced tissue remodeling, and altered transcription of inflammatory and proangiogenic genes. Targeting CDH11 reduced bone marrow–derived myeloid cells and increased proangiogenic cells in the heart 3 days after MI. Cardiac fibroblast and macrophage interactions increased IL-6 secretion in vitro. Our findings suggest that CDH11-expressing cells contribute to inflammation-driven fibrotic remodeling after MI and that targeting CDH11 with a blocking antibody improves outcomes by altering recruitment of bone marrow–derived cells, limiting the macrophage-induced expression of IL-6 by fibroblasts and promoting vascularization.

Authors

Alison K. Schroer, Matthew R. Bersi, Cynthia R. Clark, Qinkun Zhang, Lehanna H. Sanders, Antonis K. Hatzopoulos, Thomas L. Force, Susan M. Majka, Hind Lal, W. David Merryman

×

Figure 2

CDH11 mediates remodeling after MI in a partially bone marrow–derived cell–dependent manner.

Options: View larger image (or click on image) Download as PowerPoint
CDH11 mediates remodeling after MI in a partially bone marrow–derived ce...
Echocardiographic analysis of infarcted hearts revealed that ejection fraction (A), left ventricular (LV) mass (B), and LV volume (C and D) were significantly changed from baseline in all groups (A–D). In addition, Cdh11+/– and Cdh11–/– mice had significantly reduced LV mass and diastolic volume relative to Cdh11+/+ controls at 21 days after MI. WT recipients of Cdh11+/– bone marrow (E) had significantly higher EF at 21 days than at 7 days (F) and significantly lower LV mass at 7 days after MI (G) than age-matched Cdh11+/+ bone marrow recipients. There was little difference in LV volume (H and I) between donor groups. Data are presented as mean ± SEM. Significance was determined by mixed-effect analysis, with a Holms-Sidak’s multiple comparison test. *P < 0.05 relative to Cdh11+/+, #P < 0.05 relative to baseline, ^P < 0.05 between time points; color of significance marker denotes group.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts